JPRN-UMIN000011986
尚未招募
2 期
A phase 2 Study of the efficay and safty of erlotinib therapy for 3/4 stage EGFR gene mutation positive EGFR-TKI untreated non-small cell lung cancer - A phase 2 Study of the efficay and safty of erlotinib therapy for 3/4 stage EGFR gene mutation positive EGFR-TKI untreated non-small cell lung cancer
Itabashi central medical center0 个研究点目标入组 21 人2013年10月8日
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Itabashi central medical center
- 入组人数
- 21
- 状态
- 尚未招募
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •1\)Pulmonary disorder(idiopathic pulmonary fibrosis,interstitial lung disease, pneumoconiosis, active radiation pneumonia, etc.). 2\)known EGFR\-TKI resistance gene mutation(T790M) positive 3\)history of erlotinib or gefitinib treatment 4\)inable of oral drug administration 5\)history of myocardial infarction and cerebral infarction within one year 6\)planned surgery within study term 7\)history of drug allergy 8\)massive,pleural effusion or ascites 9\)uncontrolled infection or serious medical complications 10\)active concomitant malignancy 11\)mental disorder 12\)pregnant or or lactating women or those who declined contraception 13\)those judged not suitable by the attending physician
结局指标
主要结局
未指定
相似试验
招募中
2 期
A Phase II Study for the efficacy and safety of Erlotinib for Patients previously treated Non-small cell Lung Cancer Patients with EGFR Mutationson-small cell lung cancerJPRN-UMIN000003215Fujita Health Universty Hospital Division of Respirology and Allergology28
招募中
2 期
A study to test an oral combination of letrozole and everolimus for patients with advanced lung cancer who have progressed on first line chemotherapy.on Small Cell lung cancerNon Small Cell lung cancerCancer - Lung - Non small cellACTRN12607000218493Dept of Medical Oncology, Royal Adelaide Hospital20
进行中（未招募）
1 期
enalidomide, subcutaneous bortezomib, and dexamethasone treatment for multiple myelomaEUCTR2013-005008-32-IECancer Trials Ireland42
已完成
2 期
Phase II analysis for efficacy and safety of perioperative pirfenidone (Pirespa) therapy for patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis (IPF)non-small-cell lung cancer combined with idiopathic pulmonary fibrosisJPRN-UMIN000007774West Japan Oncology Group42
进行中（未招募）
1 期
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q - GFM-Aza-Rev-09Myelodysplastic Syndrome(MDS) / Acute Myeloid Leukemia(AML)MedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-011160-11-FRGroupe Francophone des Myélodysplasies (GFM)